USPTO hands win to Daiichi Sankyo in cancer drug dispute

The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Daiichi Sankyo secures nearly $46m legal fees in antibody arbitration

30 November 2023 Final award follows and incorporates the August 2022 decision by the arbitrator denying all claims levied at the Japanese company | Dispute involves antibody drug conjugate technology.

Americas

Daiichi Sankyo unit accuses Pharmacosmos of patent infringement

12 February 2020 American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

More on this story

Americas

Daiichi Sankyo unit accuses Pharmacosmos of patent infringement

12 February 2020 American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

Generics

Daiichi Sankyo secures nearly $46m legal fees in antibody arbitration

More on this story

Americas

Daiichi Sankyo unit accuses Pharmacosmos of patent infringement

12 February 2020 American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.

Generics

Daiichi Sankyo secures nearly $46m legal fees in antibody arbitration